• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于既往冠状动脉疾病、脑血管疾病和 2 型糖尿病的心血管疾病风险分层。

Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus.

机构信息

Faculty of Medicine, Niigata University, Niigata, Japan.

Kowa Company, Ltd., Tokyo, Japan.

出版信息

J Diabetes Investig. 2024 Oct;15(10):1464-1471. doi: 10.1111/jdi.14277. Epub 2024 Aug 1.

DOI:10.1111/jdi.14277
PMID:39087859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442853/
Abstract

AIMS/INTRODUCTION: History of coronary artery disease (CAD), cerebrovascular disease (CeVD), type 2 diabetes and their combined effect on cardiovascular disease are essential for cardiovascular risk management. We investigated the association of prior CAD, prior CeVD, type 2 diabetes and their combination with the risk of cardiovascular disease.

MATERIALS AND METHODS

This is a historical cohort study including 342,033 participants (aged 18-72 years) followed up for ≥5 years between 2008 and 2016. Participants were classified into eight groups (with or without prior CAD, prior CeVD and type 2 diabetes). Type 2 Diabetes was defined by fasting plasma glucose and glycated hemoglobin levels, and antidiabetic drug prescription. Prior and subsequent CAD and CeVD were identified according to claims using International Classification of Diseases 10th Revision codes, medical procedures and questionnaires. Cox regression models were used to evaluate the risk of cardiovascular events.

RESULTS

The median follow-up period was 6.4 years. The incidence of composite cardiovascular events of CAD and CeVD in the CAD-/CeVD-, CAD+/CeVD-, CAD-/CeVD+ and CAD+/CeVD+ groups were 1.92 and 6.94, 25.14 and 31.98 per 1,000 person-years in non-diabetes participants, and 8.66, 18.04, 39.98 and 60.72 in type 2 diabetes patients, respectively. Hazard ratios of cardiovascular events compared with CAD-/CeVD-/non-diabetes were 1.66 (95% confidence interval 1.55-1.78) in CAD-/CeVD-/type 2 diabetes and 1.84 (1.56-2.18) in CAD+/CeVD-/non-diabetes. CeVD+ was linked to a 4-7-fold increase in the risk of cardiovascular events regardless of CAD+ or type 2 diabetes.

CONCLUSIONS

Type 2 diabetes increased the risk of cardiovascular disease as high as a history of CAD, whereas prior CeVD alone increased the risk of future CeVD without additional effects by type 2 diabetes.

摘要

目的/引言:冠心病(CAD)、脑血管疾病(CeVD)、2 型糖尿病的病史及其对心血管疾病的综合影响对心血管风险管理至关重要。我们研究了既往 CAD、既往 CeVD、2 型糖尿病及其合并对心血管疾病风险的相关性。

材料和方法

这是一项历史队列研究,纳入了 2008 年至 2016 年期间随访时间≥5 年的 342033 名(年龄 18-72 岁)参与者。参与者分为 8 组(有无既往 CAD、既往 CeVD 和 2 型糖尿病)。2 型糖尿病的定义为空腹血糖和糖化血红蛋白水平以及抗糖尿病药物的处方。既往和随后的 CAD 和 CeVD 根据索赔使用国际疾病分类第 10 次修订版代码、医疗程序和问卷进行识别。使用 Cox 回归模型评估心血管事件的风险。

结果

中位随访时间为 6.4 年。在非糖尿病患者中,CAD-/CeVD-、CAD+/CeVD-、CAD-/CeVD+和 CAD+/CeVD+组的 CAD 和 CeVD 复合心血管事件发生率分别为 1.92 和 6.94,25.14 和 31.98/1000 人年,而在 2 型糖尿病患者中分别为 8.66、18.04、39.98 和 60.72。与 CAD-/CeVD-/非糖尿病相比,CAD-/CeVD-/2 型糖尿病患者的心血管事件风险比为 1.66(95%置信区间 1.55-1.78),CAD+/CeVD-/非糖尿病患者为 1.84(1.56-2.18)。无论是否有 2 型糖尿病,CeVD+都与心血管事件风险增加 4-7 倍相关。

结论

2 型糖尿病使心血管疾病的风险增加,与 CAD 病史一样高,而单独的既往 CeVD 增加了未来 CeVD 的风险,而无 2 型糖尿病的额外影响。

相似文献

1
Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus.基于既往冠状动脉疾病、脑血管疾病和 2 型糖尿病的心血管疾病风险分层。
J Diabetes Investig. 2024 Oct;15(10):1464-1471. doi: 10.1111/jdi.14277. Epub 2024 Aug 1.
2
Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry.糖尿病合并脑血管病患者的医疗质量。来自糖尿病合作登记处的见解。
Am J Med. 2022 Nov;135(11):1336-1341. doi: 10.1016/j.amjmed.2022.06.016. Epub 2022 Jul 22.
3
Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease: Results From the EXCEL Trial.左主干经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗有既往脑血管疾病患者的比较:EXCEL 试验结果。
JACC Cardiovasc Interv. 2018 Dec 24;11(24):2441-2450. doi: 10.1016/j.jcin.2018.09.008.
4
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.他汀类药物治疗在脑血管病与冠状动脉疾病患者中的降脂强度:来自 PALM 登记研究的见解。
J Am Heart Assoc. 2019 Oct;8(19):e013229. doi: 10.1161/JAHA.119.013229. Epub 2019 Sep 26.
5
Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese.日本人群中既往脑血管疾病和血糖状况对新发脑血管疾病的影响
Cardiovasc Diabetol. 2021 Sep 3;20(1):174. doi: 10.1186/s12933-021-01367-7.
6
Does nutritional guidance reduce cardiovascular events in patients with type 2 diabetes mellitus? A retrospective cohort study using a nationwide claims database.营养指导是否能降低 2 型糖尿病患者的心血管事件?利用全国性索赔数据库进行的回顾性队列研究。
Acta Diabetol. 2023 Nov;60(11):1541-1549. doi: 10.1007/s00592-023-02147-3. Epub 2023 Jul 8.
7
Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study.既往脑血管病患者行经皮或手术血运重建后 10 年全因死亡情况:来自 SYNTAX 扩展生存研究的见解。
Clin Res Cardiol. 2021 Oct;110(10):1543-1553. doi: 10.1007/s00392-020-01802-x. Epub 2021 Jan 30.
8
Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men.日本男性中根据葡萄糖异常状态和既往冠状动脉疾病评估的冠心病风险。
Metabolism. 2019 Dec;101:153991. doi: 10.1016/j.metabol.2019.153991. Epub 2019 Oct 27.
9
Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database.稳定性冠心病合并 2 型糖尿病但无心肌梗死或卒史且类似 THEMIS 患者:来自法国全国索赔数据库的 SNDS 的真实世界主要结局的患病率和风险。
Cardiovasc Diabetol. 2021 Nov 25;20(1):229. doi: 10.1186/s12933-021-01416-1.
10
High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.高敏肌钙蛋白 I 和 B 型利钠肽生物标志物用于预测伴或不伴糖尿病的冠状动脉疾病患者的心血管事件。
Cardiovasc Diabetol. 2019 Dec 17;18(1):171. doi: 10.1186/s12933-019-0974-2.

本文引用的文献

1
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.9. 血糖治疗的药物学方法:2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
2
Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.2 型糖尿病患者的降糖药物心血管预防:初级和次级预防类别的循证方法。
Diabetes Obes Metab. 2023 Dec;25(12):3435-3443. doi: 10.1111/dom.15226. Epub 2023 Aug 2.
3
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
2022 年美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 共识报告:2 型糖尿病患者高血糖管理。
Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.
4
Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study.2 型糖尿病发病年龄与心血管疾病及死亡率的关系:开滦研究。
Diabetes Care. 2021 Jun 1;44(6):1426-1432. doi: 10.2337/dc20-2375.
5
Temporal changes in risk of cardiovascular events in people with newly diagnosed type 2 diabetes with and without cardiovascular disease.新发 2 型糖尿病患者伴或不伴心血管疾病者心血管事件风险的时间变化。
J Diabetes Complications. 2022 Feb;36(2):108126. doi: 10.1016/j.jdiacomp.2022.108126. Epub 2022 Jan 10.
6
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.美国心脏协会关于 2 型糖尿病成人心血管危险因素综合管理的科学声明
Circulation. 2022 Mar;145(9):e722-e759. doi: 10.1161/CIR.0000000000001040. Epub 2022 Jan 10.
7
Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese.日本人群中既往脑血管疾病和血糖状况对新发脑血管疾病的影响
Cardiovasc Diabetol. 2021 Sep 3;20(1):174. doi: 10.1186/s12933-021-01367-7.
8
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
9
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.《2021年卒中与短暂性脑缺血发作患者卒中预防指南:美国心脏协会/美国卒中协会指南》
Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24.
10
Accuracy of Japanese claims data in identifying diabetes-related complications.日本索赔数据在识别糖尿病相关并发症方面的准确性。
Pharmacoepidemiol Drug Saf. 2021 May;30(5):594-601. doi: 10.1002/pds.5213. Epub 2021 Mar 4.